Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer

PURPOSE: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus bevacizumab, carboplatin, and paclitaxel (BCP) in chemotherapy-naïve nonsquamous non–small-cell lung cancer (NSCLC). We present safety and patient-reported outcomes (PROs) to provide additiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Reck, Martin, Wehler, Thomas, Orlandi, Francisco, Nogami, Naoyuki, Barone, Carlo, Moro-Sibilot, Denis, Shtivelband, Mikhail, González Larriba, Jose Luis, Rothenstein, Jeffrey, Früh, Martin, Yu, Wei, Deng, Yu, Coleman, Shelley, Shankar, Geetha, Patel, Hina, Kelsch, Claudia, Lee, Anthony, Piault, Elisabeth, Socinski, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392741/
https://www.ncbi.nlm.nih.gov/pubmed/32459597
http://dx.doi.org/10.1200/JCO.19.03158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392741/
https://www.ncbi.nlm.nih.gov/pubmed/32459597
http://dx.doi.org/10.1200/JCO.19.03158

Ejemplares similares